The risk-reward balance in drug repurposing

Does drug repurposing overcome the hurdles and pitfalls in drug development? Having conducted several recent due diligence exercises in the repurposing space, we discuss the gems and the hidden...
Learn More

Gene Therapy: Suspending Vector Immunity and Facilitating Re-Dosing?

Vector immunity is currently a major limiting factor in gene therapy. In the first place, patients with pre-existing immunity may either be ineligible for treatment or may require extremely high...
Learn More

Pharmaceutical Patents: an overview

Protecting new treatments and innovations is critical for drug developers. In this article, we provide of an overview of the history of patents, what a patent is, the general process to obtain one...
Learn More

Moving beyond cancer: CAR-T therapy takes on autoimmune disease

It’s not untypical for an emerging cancer treatments to be dubbed “revolutionary” or “game-changing”, but stepping beyond cliché, chimeric antigen receptor T-cell (“CAR-T”) therapy can rightly be...
Learn More

Monetizing the microbiome

Based on some neat guesstimating1, the number of bacteria in the gut roughly equals the number of cells in our bodies, so it’s no surprise that such a substantial (around 200g in a 70kg adult) and...
Learn More

Pharma Valuations: When to Use Incidence and/or Prevalence

Many would agree that input assumptions are the most important part of a pharma or biotech portfolio valuation. Of these, one particularly critical assumption is the addressable patient population,...
Learn More

Summer in Paris: NASH Update

Title: Summer in Paris: NASH Update Author: Peter G. Traber, MD Date: 07/16/2019 The Paris NASH meeting was held July 11 and 12, 2019, subtitled as an “International Think Tank” and it certainly did...
Learn More

No Acceptable Surrogates for NASH Cirrhosis

Title: No Acceptable Surrogates for NASH Cirrhosis Author: Peter G. Traber, MD Date: 06/06/2019 The FDA released draft guidance on developing drugs for compensated NASH cirrhosis (Nonalcoholic...
Learn More

Therapy for NASH Cirrhosis is a Distant Hope

NASH is a chronic liver disorder that results in progressive fibrosis, ultimately culminating in some patients in liver cirrhosis. In cirrhosis, the fibrotic scar tissue distorts the normal liver...
Learn More

Is Gilead’s Selonsertib for NASH Dead?

Title: Is Gilead’s Selonsertib for NASH Dead? Author: Peter G. Traber, MD Date: 02/12/2019 Introduction The search for an effective therapy for NASH with advanced fibrosis/cirrhosis suffered a major...
Learn More

Orkambi UK - Sound and Fury

By Anthony Walker, PhD, Managing Partner There’s a lot of sound and fury about Orkambi in the UK. Following a rejection from NICE, Vertex and NHS England have not been able to reach terms and the...
Learn More

Why Every Biotech Needs a Scouting Function

Alacrita frequently supports companies with their search and evaluation activities. Our scouting support is often structured to integrate with a client’s internal efforts to generate a flow of new...
Learn More
Previous
1 2 3 4 5 ... 6
Next

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2009-24 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.